| Sep 16 |
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized cancer vaccine EVX-01
|
| Sep 9 |
Evaxion reports positive mid-stage trial data on lead cancer vaccine candidate EVX-01
|
| Sep 9 |
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine candidate EVX-01
|
| Sep 9 |
Evaxion obtains pre-clinical Proof-of-Concept for mRNA Gonorrhea vaccine candidate EVX-B2
|
| Sep 9 |
EVAX Uses AI Platform to Generate Positive Treatment Data
|
| Aug 29 |
Evaxion Biotech A/S (NASDAQ:EVAX): Is Breakeven Near?
|
| Aug 14 |
Evaxion Biotech A/S 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 14 |
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
|
| Aug 14 |
Evaxion Biotech ADS reports Q2 results
|
| Aug 14 |
EVAX is a Clinical Stage AI Company Worth a Look
|
